PATENT CLAIM ANALYSIS

Application Number: 15761081
Application Type: Utility
Filing Date: 2018-03
Publication Date: 2018-09
Patent Classification: ["514", "622000"]

Abstract:
The present disclosure describes a method of treating p53-deficient cells using a niclosamide derivative according to formula (I). The present disclosure further describes a method of treating cancer using the compound according to formula I, as well as methods of screening to identify a compound that selectively target cells wherein p53 is deficient or non-functional.

Claim (Index 1):
A method of treating cancer in a patient comprising administering a pharmaceutically effective amount of a compound as defined in formula I: or derivative thereof, wherein D is N or CR 9 ; E is N or CR 10 ; F is N or CR 11 ; R 1  is H, halide, OR 12 , SR 13 , NR14, R 15 , R 2  is H, OH or OR 12 ; R 3  is H, C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl; C 6-12  aryl, C 7-14  alkaryl; C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl; or R 2  and R 3  combine to form a six-membered ring in which position 1 is connected to position 4 by R 4  and R 8  are each, independently, selected from H, halide, CF 3 , OR 28 , C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl; R 5 , R 6 , and R 7  are each, independently, selected from H, C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 6-12  aryl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl, halide, NO 2 , CO 2 H, SO 3 H, CF 3 , CN, OR 29 , SR 30 , each X 1 , X 2 , X 3 , and X 4  is, independently, O, S; or NR 38 ; Y is CR 25 R 26 , O, S, or NR 27 ; Z is O, S, or CR 50 R 51 ; each Q is, independently, O, S, or NR 52  ; R 9 , R 10 , and R 11  are each, independently, H, OH, OR 12 , C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 1-7  heteroalkyl, halide, or NO 2 ; R 12  and R 13  are each, independently, acyl, C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 6-12  aryl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl; R 17 , R 22 , R 35 , R 36 , R 37 , R 38 , and R 52  are each, independently, C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 6-12  aryl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl; R 14 , R 15 , R 16 , R 18 , R 19 , R 20 , R 21 , R 23 , R 24 , R 25 , R 26 , R 27 , R 28 , R 29 , R 30 , R 31 , R 32 , R 33 , R 34  are each, independently, H, C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 6-12  aryl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl; R 39 , R 40 , R 41 , R 42 , R 43 , R 44 , R 45 , R 46 , R 47 , R 48 , R 49 , R 50 , and R 50 , are each, independently, H, halide, CN, NO 2 , CF 3 , C 1-7  alkyl, C 2-7  alkenyl, C 2-7  alkynyl, C 2-6  heterocyclyl, C 6-12  aryl, C 7-14  alkaryl, C 3-10  alkheterocyclyl, or C 1-7  heteroalkyl, wherein the cancer comprises p53-deficient cells or cells wherein p53 is non-functional.

Metadata:
- Claim Count in Document: 32.0
- Percentile: 90.0
- Lexical Diversity: 1.53846
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14408748', '14901314', '14950033', '12604970', '10716100']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7675607859953172
- 35 USC 102 Novelty (BERT): 0.5100830250834432
- Combined Prediction Score: 0.7418130099041298
- Mean Citation Score: 283.18594799999994
- Max Citation Score: 295.15762
- Similarity Product: 223.32387954601649

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test